# Radioimmunotherapy (211At-OKT10-B10) and Chemotherapy (Melphalan) Before Stem Cell Transplantation for the Treatment of Multiple Myeloma

> **NCT04466475** · PHASE1 · WITHDRAWN · sponsor: **Fred Hutchinson Cancer Center**

## Conditions studied

- Plasma Cell Myeloma

## Interventions

- **BIOLOGICAL:** Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10
- **DRUG:** Melphalan
- **PROCEDURE:** Peripheral Blood Stem Cell Transplantation

## Key facts

- **NCT ID:** NCT04466475
- **Lead sponsor:** Fred Hutchinson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-01-27
- **Primary completion:** 2025-10-01
- **Final completion:** 2027-09-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** NIH terminated funding. Study was closed before any participants were enrolled.
- **Last updated:** 2024-01-31

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04466475

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04466475, "Radioimmunotherapy (211At-OKT10-B10) and Chemotherapy (Melphalan) Before Stem Cell Transplantation for the Treatment of Multiple Myeloma". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT04466475. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*